

PATENTS FOR OUR TOP FIVE SELLING PRODUCTS¹

The following list is intended to promote transparency regarding the innovations contained in our medicines as recognized by the patents awarded by the U.S. Patent and Trademark Office. This list reflects patents that are listed in the FDA Orange Book, are listed (or eligible for listing) in the Purple Book, and/or referenced in our 10-K Annual Report for the year ended December 31, 2025. It is expected that this list will change over time to reflect, for example, patent expirations and newly granted patents.

Product Name - Ingredients	US Patent Number	General Subject Matter
Biktarvy® (bictegravir, emtricitabine, tenofovir alafenamide)		
	8754065	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
	9216996	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin- es and methods for treating viral infections
	9296769	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
	9708342	SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B][1,3]OXAZEPIN-8-OLATE
	9732092	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1',2':4,5]pyrazino[2,1-b][1,3]OXAZEPIN- ES and methods for treating viral infections
	10385067	SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B][1,3]OXAZEPIN-8-OLATE
	10548846	THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
	11744802	THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
	12594244	THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
Descovy® (emtricitabine, tenofovir alafenamide)		
	8754065	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
	9296769	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Genvoya® (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)	12629338	PHARMACEUTICAL FORMULATIONS
	7176220	4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT
	7635704	STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
	8148374	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
	8633219	COMBINATION THERAPY
	8754065	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
	8981103	STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
	9296769	TENOFOVIR ALAFENAMIDE HEMIFUMARATE

¹ Based on total product sales for the year ended December 31, 2025.

Product Name - Ingredients	US Patent Number	General Subject Matter
	9891239	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
	10039718	USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Yescarta® (axicabtagene ciloleucel)	7741465	CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH
	9855298	METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
	10322146	METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
	11,779,601	DIAGNOSTIC METHODS FOR T CELL THERAPY
Epclusa® (sofosbuvir, velpatasvir)	7964580	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
	8334270	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
	8575135	ANTIVIRAL COMPOUNDS
	8580765	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
	8618076	NUCLEOSIDE PHOSPHORAMIDATES
	8633309	NUCLEOSIDE PHOSPHORAMIDATES
	8735372	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
	8889159	COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS
	8921341	ANTIVIRAL COMPOUNDS
	8940718	ANTIVIRAL COMPOUNDS
	9085573	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
	9284342	NUCLEOSIDE PHOSPHORAMIDATES
	11116783	COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
	11707479	COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS